CL2007002766A1 - Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par - Google Patents

Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par

Info

Publication number: CL2007002766A1
Authority: CL; Chile
Prior art keywords: composition; granulum; pyrimidil; benzamide; capsule
Prior art date: 2006-09-27

Application number

CL200702766A

Other languages

English (en)

Inventor

Nathalie Bruneau

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-27

Filing date

2007-09-26

Publication date

2008-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-26 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-08 Publication of CL2007002766A1 publication Critical patent/CL2007002766A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL200702766A 2006-09-27 2007-09-26 Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par CL2007002766A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06121371A EP1923053A1 (en)	2006-09-27	2006-09-27	Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number	Publication Date
CL2007002766A1 true CL2007002766A1 (es)	2008-08-08

Family

ID=37684496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702766A CL2007002766A1 (es)	2006-09-27	2007-09-26	Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par

Country Status (34)

Country	Link
US (2)	US8293756B2 (es)
EP (4)	EP1923053A1 (es)
JP (2)	JP5567340B2 (es)
KR (2)	KR20090076931A (es)
CN (2)	CN101516344A (es)
AR (1)	AR062980A1 (es)
AU (1)	AU2007301977B2 (es)
BR (1)	BRPI0719438B1 (es)
CA (1)	CA2662571C (es)
CL (1)	CL2007002766A1 (es)
CO (1)	CO6160288A2 (es)
CY (2)	CY1117021T1 (es)
DK (2)	DK2068839T3 (es)
ES (3)	ES2556625T5 (es)
FI (2)	FI3984528T3 (es)
HR (2)	HRP20151383T4 (es)
HU (2)	HUE063083T2 (es)
IL (1)	IL197496A (es)
JO (1)	JO3757B1 (es)
LT (1)	LT3984528T (es)
MA (1)	MA30807B1 (es)
MX (1)	MX2009003184A (es)
MY (1)	MY148237A (es)
NO (2)	NO347404B1 (es)
NZ (1)	NZ575317A (es)
PE (2)	PE20120626A1 (es)
PL (2)	PL3984528T3 (es)
PT (2)	PT3984528T (es)
RU (1)	RU2469707C2 (es)
SI (2)	SI3984528T1 (es)
TN (1)	TN2009000093A1 (es)
TW (3)	TWI540128B (es)
WO (1)	WO2008037716A2 (es)
ZA (1)	ZA200901511B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1923053A1 (en) *	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt
EP2482820A2 (en)	2009-09-28	2012-08-08	Medizinische Universität Wien	New use of pdgfrbeta inhibitors
MX2012004709A (es) *	2009-10-23	2012-05-23	Novartis Ag	Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar)	2009-11-17	2020-08-27	Novartis Ag	طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (en) *	2011-06-02	2012-12-06	Hetero Research Foundation	Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) *	2011-06-14	2014-01-29	Novartis Ag	4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) *	2011-08-12	2012-01-18	西安交通大学	一种尼罗替尼的制备方法
PH12014500897A1 (en)	2011-10-28	2019-10-07	Novartis Ag	Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
AR088844A1 (es) *	2011-11-14	2014-07-10	Novartis Ag	Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
US9301957B2 (en)	2011-11-14	2016-04-05	Novartis Ag	Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
BR112015000349A2 (pt)	2012-07-11	2017-06-27	Novartis Ag	método de tratamento de tumores estromais gastrointestinais
US9682081B2 (en)	2013-04-25	2017-06-20	Sun Pharmaceutical Industries Limited	Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en)	2013-11-12	2017-05-02	Ayyappan K. Rajasekaran	Kinase inhibitors
HRP20220358T1 (hr)	2014-08-11	2022-05-13	Sun Pharmaceutical Industries Limited	Nove soli nilotiniba i njihovi polimorfi
WO2016033304A1 (en) *	2014-08-28	2016-03-03	Codexis, Inc.	Imidazoyl anilide derivatives and methods of use
ES2935158T3 (es) *	2016-03-17	2023-03-02	Sun Pharmaceutical Ind Ltd	Composición farmacéutica de nilotinib
CN107582531B (zh) *	2016-07-06	2020-12-29	四川科伦药物研究院有限公司	一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) *	2017-08-04	2020-11-03	北京化工大学	一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) *	2017-08-08	2020-05-22	南方医科大学	尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs)	2017-12-20	2019-07-03	Zentiva, K.S.	Léková forma obsahující krystalický nilotinib
CN112423757A (zh)	2018-06-15	2021-02-26	汉达生技医药责任有限公司	激酶抑制剂的盐类及其组合物
CA3168680A1 (en) *	2020-01-31	2021-08-05	Nanocopoeia, Llc	Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en)	2020-04-30	2023-03-08	Nanocopoeia LLC	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) *	2020-07-20	2024-05-24	日本化薬株式会社	ニロチニブ錠剤
JP2023543815A (ja)	2020-09-29	2023-10-18	シェンチェンファーマシンシーオー．，エルティーディー．	医薬組成物
CA3224750A1 (en)	2021-06-19	2022-12-22	Helm Ag	Granulate composition comprising nilotinib
WO2023285981A1 (en) *	2021-07-15	2023-01-19	Torrent Pharmaceuticals Limited	Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en)	2021-07-23	2023-01-25	KRKA, d.d., Novo mesto	Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en)	2022-04-11	2023-10-18	Lotus Pharmaceutical Co., Ltd.	Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
EP4642435A1 (en)	2022-12-29	2025-11-05	Renata Pharmaceuticals (Ireland) Limited	Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) *	2023-03-22	2024-09-26	Unichem Laboratories Limited	A stable pharmaceutical composition and process for preparing thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4072535A (en) *	1970-12-28	1978-02-07	A. E. Staley Manufacturing Company	Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) *	1990-09-01	2001-01-15	大正製薬株式会社	ソファルコン含有固形製剤
HU217629B (hu) *	1991-12-12	2000-03-28	Novartis Ag.	Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
CA2560523C (en)	1996-07-24	2011-09-20	Celgene Corporation	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
TW426516B (en) *	1996-12-06	2001-03-21	Fujisawa Pharmaceutical Co	An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) *	1998-09-17	2000-11-24	Cll Pharma	Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) *	1999-07-09	2004-05-28	Ethypharm Lab Prod Ethiques	Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
DK1200090T3 (da)	1999-08-03	2013-11-25	Icos Corp	Farmaceutisk formulering omfattende en beta-carbolin og dens anvendelse til behandling af seksuel dysfunktion
HRP20010582A2 (en) *	1999-12-08	2002-08-31	Pharmacia Corp	Valdecoxib compositions
NZ519984A (en)	2000-01-07	2004-03-26	Transform Pharmaceuticals Inc	High-throughput formation, identification, and analysis of diverse solid-forms
US20060257482A1 (en) *	2002-06-07	2006-11-16	Patrik Kumar	Modified release, multiple unit drug delivery systems
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
AU2003288182A1 (en) *	2002-11-26	2004-06-18	Universiteit Gent	Process and apparatus for continuous wet granulation of power material
KR20040076203A (ko) *	2003-02-24	2004-08-31	주식회사 엘지생명과학	음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
WO2005011635A2 (en) *	2003-08-04	2005-02-10	Pfizer Products Inc.	Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
TR200301553A1 (tr)	2003-09-18	2005-10-21	Nobel �La� Sanay�� Ve T�Caret A.�.	İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en)	2003-10-27	2003-12-03	Novartis Ag	Organic compounds
WO2005065653A1 (en) *	2003-12-19	2005-07-21	E.I. Du Pont De Nemours And Company	Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en)	2004-07-28	2007-04-25	Ranbaxy Laboratories Limited	Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
CN101031285A (zh) *	2004-10-01	2007-09-05	卫材R&D管理有限公司	含有微粒的组合物及其制备方法
WO2006066932A1 (en) *	2004-12-24	2006-06-29	Lek Pharmaceuticals D.D.	Stable pharmaceutical composition comprising an active substance in the form of solid solution
MX2007009135A (es) *	2005-01-28	2007-09-06	Novartis Ag	Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
RU2007135284A (ru) *	2005-02-25	2009-03-27	Новартис АГ (CH)	Фармацевтические комбинации ингибиторов киназ bcr-abl и raf
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es)	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
RU2454220C2 (ru) *	2006-08-16	2012-06-27	Новартис Аг	Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP1923053A1 (en)	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt

2006
- 2006-09-27 EP EP06121371A patent/EP1923053A1/en not_active Ceased
2007
- 2007-09-23 JO JOP/2007/0402A patent/JO3757B1/ar active
- 2007-09-25 US US12/442,544 patent/US8293756B2/en active Active
- 2007-09-25 NZ NZ575317A patent/NZ575317A/en unknown
- 2007-09-25 DK DK07820560.6T patent/DK2068839T3/da active
- 2007-09-25 LT LTEP21194622.3T patent/LT3984528T/lt unknown
- 2007-09-25 EP EP15184282.0A patent/EP3009128B1/en active Active
- 2007-09-25 NO NO20220946A patent/NO347404B1/no unknown
- 2007-09-25 PL PL21194622.3T patent/PL3984528T3/pl unknown
- 2007-09-25 CN CNA2007800353567A patent/CN101516344A/zh active Pending
- 2007-09-25 RU RU2009115782/15A patent/RU2469707C2/ru active
- 2007-09-25 PT PT211946223T patent/PT3984528T/pt unknown
- 2007-09-25 PL PL07820560.6T patent/PL2068839T5/pl unknown
- 2007-09-25 FI FIEP21194622.3T patent/FI3984528T3/fi active
- 2007-09-25 KR KR1020097008418A patent/KR20090076931A/ko not_active Withdrawn
- 2007-09-25 PE PE2012000043A patent/PE20120626A1/es not_active Application Discontinuation
- 2007-09-25 ES ES07820560T patent/ES2556625T5/es active Active
- 2007-09-25 ES ES15184282T patent/ES2957912T3/es active Active
- 2007-09-25 CA CA2662571A patent/CA2662571C/en active Active
- 2007-09-25 KR KR1020147027439A patent/KR101598747B1/ko active Active
- 2007-09-25 FI FIEP07820560.6T patent/FI2068839T4/fi active
- 2007-09-25 SI SI200732199T patent/SI3984528T1/sl unknown
- 2007-09-25 SI SI200731724T patent/SI2068839T2/sl unknown
- 2007-09-25 AU AU2007301977A patent/AU2007301977B2/en active Active
- 2007-09-25 NO NO20091501A patent/NO346639B1/no unknown
- 2007-09-25 CN CN201410535689.8A patent/CN104306350A/zh active Pending
- 2007-09-25 PE PE2007001294A patent/PE20081379A1/es active IP Right Grant
- 2007-09-25 MY MYPI20091044A patent/MY148237A/en unknown
- 2007-09-25 ES ES21194622T patent/ES2951547T3/es active Active
- 2007-09-25 HU HUE21194622A patent/HUE063083T2/hu unknown
- 2007-09-25 PT PT78205606T patent/PT2068839E/pt unknown
- 2007-09-25 EP EP07820560.6A patent/EP2068839B2/en active Active
- 2007-09-25 BR BRPI0719438-2A patent/BRPI0719438B1/pt active IP Right Grant
- 2007-09-25 DK DK21194622.3T patent/DK3984528T3/da active
- 2007-09-25 HR HRP20151383TT patent/HRP20151383T4/hr unknown
- 2007-09-25 JP JP2009529688A patent/JP5567340B2/ja active Active
- 2007-09-25 EP EP21194622.3A patent/EP3984528B1/en active Active
- 2007-09-25 AR ARP070104231A patent/AR062980A1/es not_active Application Discontinuation
- 2007-09-25 HR HRP20230753TT patent/HRP20230753T3/hr unknown
- 2007-09-25 HU HUE07820560A patent/HUE028204T2/en unknown
- 2007-09-25 MX MX2009003184A patent/MX2009003184A/es active IP Right Grant
- 2007-09-25 WO PCT/EP2007/060165 patent/WO2008037716A2/en not_active Ceased
- 2007-09-26 TW TW102144088A patent/TWI540128B/zh active
- 2007-09-26 TW TW096135768A patent/TWI428333B/zh active
- 2007-09-26 CL CL200702766A patent/CL2007002766A1/es unknown
- 2007-09-26 TW TW103101056A patent/TW201418245A/zh unknown
2009
- 2009-03-03 ZA ZA2009/01511A patent/ZA200901511B/en unknown
- 2009-03-09 IL IL197496A patent/IL197496A/en active IP Right Grant
- 2009-03-19 TN TN2009000093A patent/TN2009000093A1/fr unknown
- 2009-04-22 MA MA31809A patent/MA30807B1/fr unknown
- 2009-04-24 CO CO09041795A patent/CO6160288A2/es unknown
2012
- 2012-09-21 US US13/624,354 patent/US8501760B2/en active Active
2013
- 2013-11-07 JP JP2013231327A patent/JP2014065715A/ja active Pending
2015
- 2015-12-16 CY CY20151101150T patent/CY1117021T1/el unknown
2023
- 2023-07-27 CY CY20231100367T patent/CY1126116T1/el unknown

Also Published As

Publication number	Publication date
ES2951547T3 (es)	2023-10-23
CO6160288A2 (es)	2010-05-20
HK1133193A1 (en)	2010-03-19
JP5567340B2 (ja)	2014-08-06
IL197496A (en)	2016-04-21
NO346639B1 (no)	2022-11-07
RU2009115782A (ru)	2010-11-10
IL197496A0 (en)	2009-12-24
PL2068839T5 (pl)	2023-01-30
US20100087463A1 (en)	2010-04-08
US8293756B2 (en)	2012-10-23
KR20090076931A (ko)	2009-07-13
EP3009128B1 (en)	2023-07-05
PT2068839E (pt)	2015-12-30
CY1126116T1 (el)	2023-11-15
KR20140121903A (ko)	2014-10-16
ES2556625T3 (es)	2016-01-19
CA2662571A1 (en)	2008-04-03
FI3984528T3 (fi)	2023-07-27
EP3984528B1 (en)	2023-07-05
MY148237A (en)	2013-03-29
HUE028204T2 (en)	2016-12-28
PE20120626A1 (es)	2012-06-07
PE20081379A1 (es)	2008-11-27
SI3984528T1 (sl)	2023-09-29
AU2007301977B2 (en)	2011-09-08
EP1923053A1 (en)	2008-05-21
TWI428333B (zh)	2014-03-01
NO20220946A1 (no)	2009-04-24
TWI540128B (zh)	2016-07-01
NO20091501L (no)	2009-04-24
DK2068839T3 (da)	2016-01-11
MX2009003184A (es)	2009-04-03
AR062980A1 (es)	2008-12-17
PL3984528T3 (pl)	2023-08-28
SI2068839T2 (sl)	2023-01-31
EP2068839B2 (en)	2022-10-12
AU2007301977A1 (en)	2008-04-03
TW201418244A (zh)	2014-05-16
WO2008037716A2 (en)	2008-04-03
US20130023549A1 (en)	2013-01-24
ES2556625T5 (es)	2023-03-02
HRP20230753T3 (hr)	2023-10-27
ES2957912T3 (es)	2024-01-29
ZA200901511B (en)	2010-02-24
EP2068839A2 (en)	2009-06-17
TW201418245A (zh)	2014-05-16
PL2068839T3 (pl)	2016-06-30
US8501760B2 (en)	2013-08-06
NO347404B1 (no)	2023-10-16
MA30807B1 (fr)	2009-10-01
FI2068839T4 (fi)	2023-01-31
WO2008037716A3 (en)	2008-07-17
HRP20151383T4 (hr)	2023-03-03
SI2068839T1 (sl)	2016-02-29
EP3009128A1 (en)	2016-04-20
BRPI0719438A2 (pt)	2013-12-10
DK3984528T3 (da)	2023-07-31
PT3984528T (pt)	2023-08-07
BRPI0719438B1 (pt)	2022-04-19
TW200821298A (en)	2008-05-16
RU2469707C2 (ru)	2012-12-20
JO3757B1 (ar)	2021-01-31
NZ575317A (en)	2011-12-22
EP2068839B1 (en)	2015-09-23
EP3984528A1 (en)	2022-04-20
JP2010504942A (ja)	2010-02-18
TN2009000093A1 (en)	2010-08-19
CN101516344A (zh)	2009-08-26
CA2662571C (en)	2016-09-27
LT3984528T (lt)	2023-08-10
CY1117021T1 (el)	2017-04-05
KR101598747B1 (ko)	2016-03-02
CN104306350A (zh)	2015-01-28
HUE063083T2 (hu)	2023-12-28
HRP20151383T1 (hr)	2016-01-15
JP2014065715A (ja)	2014-04-17

Publication	Publication Date	Title
CL2007002766A1 (es)	2008-08-08	Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par
WO2010146179A3 (en)	2011-04-14	Solid pharmaceutical composition comprising rivaroxaban
LT2046298T (lt)	2017-03-27	Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
NO20090593L (no)	2009-04-07	Modulatorer av farmakokinetikkegenskaper til terapeutika
IL195174A0 (en)	2009-08-03	Percutaneous absorption preparations of antidementia drugs
BRPI0520669A2 (pt)	2009-06-02	dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
IL193727A0 (en)	2009-05-04	Dosage forms for administering combinations of drugs
IL199472A0 (en)	2010-03-28	Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
WO2009081174A3 (en)	2009-08-27	Anti - retroviral combination
CO6400186A2 (es)	2012-03-15	Tabletas de acetato de ulipristal
ECSP088980A (es)	2009-02-27	Composicion farmacéutica que comprende amlodipina y losartán
EA200970449A1 (ru)	2009-08-28	Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность
ECSP099536A (es)	2009-08-28	Métodos y formulaciones para biodisponibilidad mejorada de antiprogestinas
IL194961A0 (en)	2009-08-03	Compounds a-r-x for the manufacture of pharmaceutical preparations
WO2008005742A3 (en)	2008-07-10	Ibuprofen-containing liquid filled hard capsules
WO2010012459A3 (en)	2010-08-05	A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
ZA200807348B (en)	2009-08-26	Dosage aerosols for the administration of pharmaceutical preparations
WO2011064558A3 (en)	2012-02-02	Pharmaceutical composition
PL2071917T3 (pl)	2013-04-30	System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
WO2008081268A3 (en)	2009-08-27	Pharmaceutical compositions of entacapone
WO2007110765A3 (en)	2009-04-16	Processes for the preparation of octreotide
WO2010079433A3 (en)	2010-12-29	Pharmaceutical composition comprising melogliptin
WO2009132082A3 (en)	2009-12-30	Immunogenic compositions containing ceramide and methods of use thereof
EA201190282A1 (ru)	2012-04-30	Фармацевтическая композиция, содержащая тамсулозин